Form 4 for IMRX Immuneering Corp
Accepted 2022-04-14 00:00:00 ET · period of report 2022-04-12 · accession 0001415889-22-004065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-14 | 2022-04-12 | IMRX | Zeskind Benjamin J. | Pres AND CEO, Dir, 10% | M - OptEx | $3.01 | +2,000 | 2.26M | +0.1% | +$6,020 |
| D | 2022-04-14 | 2022-04-12 | IMRX | Zeskind Benjamin J. | Pres AND CEO, Dir, 10% | M - OptEx | $0.00 | -2,000 | 206.0K | -1.0% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-04-12 | M | A | 2,000 | $3.01 | 2,259,352 | D | — | — | |
| 2 | Derivative | Stock Option | 2022-04-12 | M | D | 2,000 | $0.00 | 206,000 | D | $3.01 · — to 2029-12-15 | 2,000 Class A Common Stock | (F2) The option has fully vested and is currently exercisable. |